Pfizer Inc - Company Profile
Powered by 
All the sales intelligence you need on Pfizer Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Pfizer Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Pfizer Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View morePfizer Inc (Pfizer) is a research-based biopharmaceutical company. It discovers, develops, manufactures, markets, sells, and distributes medicines and vaccines. The company's products address a wide range of therapeutic areas such as anti-infectives, oncology, cardiovascular, diabetes, obesity, inflammation, immunology, rare diseases, and bacterial infections. Pfizer's products are used by healthcare providers, hospitals, clinics, and pharmacies to treat various medical conditions. The company distributes products through a network of wholesalers, retailers, and government agencies through brands such as Zavzpret, Abrysvo, Inflectra, Genotropin, Octagam, and Bosulif, among others. It operates manufacturing units in Belgium, India, Germany, Ireland, Italy, Japan, Singapore, and the US, among others. Pfizer is headquartered in New York, the US.
Headquarters
United States of America
Address
66 Hudson Boulevard East, New York City, 10001-2192
Website
www.pfizer.com
Telephone
1 212 7332323
No of Employees
75,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PFE (NYSE)
Revenue (2024)
$62.6B
-1.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-3.2%
(2024 vs 2023)
Market Cap*
$136.1B
Net Profit Margin (2024)
XYZ
-1.6%
(2024 vs 2023)
* As of and is in US$
Pfizer Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Therapy Areas: | Service: | Celebrex |
| Internal Medicine | Contract Manufacturing Services | Eliquis |
| Inflammation and Immunology | PfizerForAll | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In May, the company secured the European Commission's marketing authorization to develop the approved indication for HYMPAVZI. |
| 2026 | Regulatory Approval | In May, the company received approval from the European Commission for HYMPAVZI for the treatment of adults and adolescents with hemophilia A or B with inhibitors. |
| 2026 | Contracts/Agreements | In May, the company signed a licensing agreement with Innovent Biologics to jointly develop a portfolio of 12 oncology programs spanning antibody-drug conjugates and multispecific antibodies. |
Competitor Comparison
| Key Parameters | Pfizer Inc | Johnson & Johnson | Eli Lilly and Co | Merck & Co Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | New York City | New Brunswick | Indianapolis | Rahway | North Chicago |
| State/Province | New York | New Jersey | Indiana | New Jersey | Illinois |
| No. of Employees | 75,000 | 138,200 | 50,605 | 75,000 | 57,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Albert Bourla, PhD | Chief Executive Officer; Chairman | Executive Board | 2020 | 64 |
| David M. Denton | Executive Vice President; Chief Financial Officer | Senior Management | 2022 | 60 |
| Dennis Hancock | Chief Information Officer; Executive Vice President | Senior Management | 2026 | - |
| Douglas M. Lankler | Chief Legal Officer; Executive Vice President | Senior Management | 2025 | 60 |
| Patrizia Cavazzoni, MD | Chief Medical Officer; Executive Vice President | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer